Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The monoclonal antibody VYD2311 potently neutralizes dominant and emerging SARS-CoV-2 variants
Ian A. Mellis, Madeline Wu, Kristin Daniel, Hsiang Hong, Yicheng Guo, David D. Ho
Ian A. Mellis, Madeline Wu, Kristin Daniel, Hsiang Hong, Yicheng Guo, David D. Ho
View: Text | PDF
Research Letter Infectious disease Public Health

The monoclonal antibody VYD2311 potently neutralizes dominant and emerging SARS-CoV-2 variants

  • Text
  • PDF
Abstract

Authors

Ian A. Mellis, Madeline Wu, Kristin Daniel, Hsiang Hong, Yicheng Guo, David D. Ho

×

Figure 1

Neutralizing activity of research-grade VYD2311 and research-grade pemivibart.

Options: View larger image (or click on image) Download as PowerPoint
Neutralizing activity of research-grade VYD2311 and research-grade pemiv...
Percent neutralization of the indicated pseudotyped viruses by VYD2311 (red) and pemivibart (blue). Dots indicate technical replicates, squares indicate mean, I bars indicate standard deviation. Five-fold serial dilutions from a maximum tested concentration of 250 μg/mL, 9 doses tested. Dashed lines indicate 50% and 90% neutralizations. The indicated inhibitory concentrations (ICs) of each antibody at 50% and 90% neutralization levels against each variant are annotated above each pair of curves.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts